Shree Ganesh Biotech India Ltd
Incorporated in 1982, Shree Ganesh Biotech Ltd is engaged in the trading of seeds and bhushi.[1]
- Market Cap ₹ 24.7 Cr.
- Current Price ₹ 0.62
- High / Low ₹ 1.08 / 0.58
- Stock P/E
- Book Value ₹ 1.60
- Dividend Yield 0.00 %
- ROCE 0.62 %
- ROE 0.44 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Stock is trading at 0.40 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 1.57% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Biotechnology
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.26 | 1.68 | 2.12 | 8.54 | 7.86 | 5.87 | 2.47 | 17.21 | 72.64 | 62.45 | 20.28 | 22.96 | 5.86 | |
| 1.84 | 1.17 | 1.47 | 4.78 | 4.36 | 4.08 | 2.23 | 16.50 | 69.19 | 60.30 | 20.48 | 24.01 | 7.82 | |
| Operating Profit | 0.42 | 0.51 | 0.65 | 3.76 | 3.50 | 1.79 | 0.24 | 0.71 | 3.45 | 2.15 | -0.20 | -1.05 | -1.96 |
| OPM % | 18.58% | 30.36% | 30.66% | 44.03% | 44.53% | 30.49% | 9.72% | 4.13% | 4.75% | 3.44% | -0.99% | -4.57% | -33.45% |
| 0.00 | 0.00 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | -0.28 | 0.05 | 0.56 | 1.06 | 1.44 | 1.67 | |
| Interest | 0.04 | 0.07 | 0.07 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.21 | 0.10 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.17 | 0.34 | 0.55 | 3.73 | 3.50 | 1.79 | 0.24 | 0.43 | 3.50 | 2.71 | 0.86 | 0.39 | -0.29 |
| Tax % | 0.00% | 0.00% | 1.82% | 0.00% | 0.00% | 0.00% | 0.00% | 25.58% | 27.71% | 25.09% | 26.74% | 28.21% | |
| 0.17 | 0.34 | 0.54 | 3.73 | 3.50 | 1.79 | 0.24 | 0.32 | 2.53 | 2.04 | 0.62 | 0.28 | -0.29 | |
| EPS in Rs | 0.05 | 0.09 | 0.15 | 1.01 | 0.95 | 0.04 | 0.01 | 0.01 | 0.06 | 0.05 | 0.02 | 0.01 | 0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 30% |
| 5 Years: | 56% |
| 3 Years: | -32% |
| TTM: | -75% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -2% |
| 5 Years: | 3% |
| 3 Years: | -52% |
| TTM: | -116% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -36% |
| 3 Years: | -20% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 0% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.83 | 1.83 | 1.83 | 1.83 | 1.83 | 19.93 | 19.93 | 19.93 | 19.93 | 39.86 | 39.86 | 39.86 | 39.86 |
| Reserves | 2.06 | 2.41 | 2.94 | 17.54 | 21.04 | 37.31 | 37.54 | 37.86 | 40.39 | 22.49 | 23.12 | 23.39 | 23.73 |
| 0.33 | 0.61 | 0.50 | 0.06 | 0.19 | 0.19 | 0.19 | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 | 1.43 | |
| 0.08 | 0.12 | 0.03 | 0.01 | 3.30 | 6.66 | 7.06 | 16.64 | 33.24 | 17.18 | 10.64 | 0.24 | 0.12 | |
| Total Liabilities | 4.30 | 4.97 | 5.30 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 65.14 |
| 2.38 | 2.40 | 2.32 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.21 | 0.21 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 3.06 | 3.22 | 0.00 | 0.00 | 9.15 | 9.15 |
| 1.71 | 2.36 | 2.77 | 19.44 | 26.36 | 64.08 | 64.72 | 71.56 | 90.34 | 79.53 | 73.62 | 54.34 | 55.99 | |
| Total Assets | 4.30 | 4.97 | 5.30 | 19.44 | 26.36 | 64.09 | 64.72 | 74.62 | 93.56 | 79.53 | 73.62 | 63.49 | 65.14 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.19 | -0.07 | -0.04 | -12.94 | 2.23 | -0.50 | -1.01 | 2.36 | 3.57 | 10.54 | 10.16 | -10.21 | |
| -0.33 | -0.11 | 0.00 | 2.53 | -2.36 | -32.07 | 0.99 | -2.36 | -3.37 | -10.09 | -10.21 | 9.80 | |
| 0.14 | 0.28 | -0.11 | 10.42 | 0.13 | 32.58 | 0.00 | 0.00 | -0.19 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | 0.00 | 0.10 | -0.16 | 0.02 | 0.00 | 0.01 | -0.02 | 0.01 | 0.01 | 0.44 | -0.05 | -0.41 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 92.06 | 260.71 | 456.25 | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 0.00 |
| Inventory Days | 298.37 | 483.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 46.59 |
| Days Payable | 20.28 | 46.27 | 0.00 | |||||||||
| Cash Conversion Cycle | 370.15 | 697.69 | 456.25 | 384.23 | 627.84 | 1,191.38 | 3,072.21 | 601.05 | 220.54 | 112.98 | 59.39 | 46.59 |
| Working Capital Days | 251.95 | 310.68 | 380.50 | 383.81 | 475.99 | 779.12 | 2,036.32 | 249.20 | 53.71 | 12.80 | -132.11 | 50.08 |
| ROCE % | 5.17% | 9.04% | 12.25% | 30.45% | 16.47% | 4.45% | 0.42% | 1.23% | 5.92% | 4.42% | 1.37% | 0.62% |
Documents
Announcements
-
Disclosure Under Regulation 32(1) Of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015
29 Jan - No unutilised proceeds from past public/right/preferential/QIP issues as of 31 Dec 2025.
-
Regulations 30, 33 And Other Applicable Provisions Of The SEBI (LODR) Regulations, 2015
29 Jan - Approved unaudited Q3 and nine-month results to Dec 31, 2025; Q3 PAT ₹32.23 lakh, 9M PAT ₹66.34 lakh.
-
Board Meeting Outcome for Outcome Of The Board Meeting Of The Board Held On 29Th January 2026.
29 Jan - Board approved unaudited Q3/9M results to 31-Dec-2025: total income ₹106.90L, profit ₹32.23L.
-
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations, 2015 - Intimation Of Board Meeting.
19 Jan - Board meeting 29 Jan 2026 to approve unaudited results for quarter and nine months ended 31 Dec 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Jan - RTA certificate for quarter ended 31 Dec 2025; no physical demat requests.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
Business Overview:[1][2]
SGBL is engaged in the business of production,
processing and marketing of high-quality hybrid seeds for different crops like corn, sunflower, cotton, paddy, grain sorghum, etc. The
company provides crop solutions to the farmer
by supplying high yielding hybrid seeds and crop management namely micro nutrients, bio
products etc.